The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET
Open accessAbstract
UNLABELLED: Functional techniques are playing a pivotal role in the imaging of cancer today. Our aim was to compare, on a head-to-head basis, 3 functional imaging techniques in patients with histologically verified neuroendocrine tumors: somatostatin receptor scintigraphy (SRS) with (111)In-diethylenetriaminepentaacetic acid-octreotide, scintigraphy with (123)I-metaiodobenzylguanidine (MIBG), and (18)F-FDG PET. METHODS: Ninety-six prospectively enrolled patients with neuroendocrine tumors underwent SRS, (123)I-MIBG scintigraphy, and (18)F-FDG PET on average within 40 d. The functional images were fused with low-dose CT scans for anatomic localization, and the imaging results were compared with the proliferation index as determined by Ki67. RESULTS: The overall sensitivity of SRS, (123)I-MIBG scintigraphy, and (18)F-FDG PET was 89%, 52%, and 58%, respectively. Of the 11 SRS-negative patients, 7 were (18)F-FDG PET-positive, of which 3 were also (123)I-MIBG scintigraphy-positive, giving a combined overall sensitivity of 96%. SRS also exceeded (123)I-MIBG scintigraphy and (18)F-FDG PET based on the number of lesions detected (393, 185, and 225, respectively) and tumor subtypes. (123)I-MIBG scintigraphy was superior to (18)F-FDG PET for ileal neuroendocrine tumors, and (18)F-FDG PET was superior to (123)I-MIBG scintigraphy for pancreaticoduodenal neuroendocrine tumors. The sensitivity of (18)F-FDG PET (92%) exceeded that of both SRS (69%) and (123)I-MIBG scintigraphy (46%) for tumors with a proliferation index above 15%. CONCLUSION: The overall sensitivity of (123)I-MIBG scintigraphy and (18)F-FDG PET was low compared with SRS. However, for tumors with a high proliferation rate, (18)F-FDG PET had the highest sensitivity. The results indicate that, although SRS should still be the routine method, (18)F-FDG PET provides complementary diagnostic information and is of value for neuroendocrine tumor patients with negative SRS findings or a high proliferation index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Yao, J. C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J. E., Abdalla, E. K., Fleming, J. B., Vauthey, J.-N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4377 · Cited by 4,510
A 5‐decade analysis of 13,715 carcinoid tumors
Modlin, I. M., Lye, K. D., & Kidd, M. (2003) · Cancer · doi:10.1002/cncr.11105 · Cited by 2,734
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system
Rindi, G., Klöppel, G., Alhman, H., Caplin, M., Couvelard, A., de Herder, W. W., Erikssson, B., Falchetti, A., Falconi, M., Komminoth, P., et al. (2006) · Virchows Archiv · doi:10.1007/s00428-006-0250-1 · Cited by 1,547
Rindi, G., Klöppel, G., Couvelard, A., Komminoth, P., Körner, M., Lopes, J. M., McNicol, A.-M., Nilsson, O., Perren, A., Scarpa, A., et al. (2007) · Virchows Archiv · doi:10.1007/s00428-007-0452-1 · Cited by 955
The Gastroenteropancreatic Neuroendocrine Cell System and Its Tumors: The WHO Classification
KLÖPPEL, G., PERREN, A., & HEITZ, P. U. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1294.002 · Cited by 794
Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T., Jurlander, J., Buus, S., Keiding, S., D'Amore, F., Boesen, A.-M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2252 · Cited by 726
Self-citationReubi, J., Waser, B., Schaer, J.-C., & Laissue, J. A. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100541 · Cited by 657
Buchmann, I., Henze, M., Engelbrecht, S., Eisenhut, M., Runz, A., Schäfer, M., Schilling, T., Haufe, S., Herrmann, T., & Haberkorn, U. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0450-1 · Cited by 506
Fynn, R. W. (1959) · PubMed · Cited by 502
Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours
Plöckinger, U., Rindi, G., Arnold, R., Eriksson, B., Krenning, E. P., de Herder, W. W., Goede, A., Caplin, M., Öberg, K., Reubi, J. C., et al. (2004) · Neuroendocrinology · doi:10.1159/000085237 · Cited by 477
Kayani, I., Bomanji, J. B., Groves, A., Conway, G., Gacinovic, S., Win, T., Dickson, J., Caplin, M., & Ell, P. J. (2008) · Cancer · doi:10.1002/cncr.23469 · Cited by 477
Kwekkeboom, D. J., Mueller‐Brand, J., Paganelli, G., Anthony, L. B., Pauwels, S. A., Kvols, L. K., O’Dorisio, T. M., Valkema, R., Bodei, L., Chinol, M., et al. (2005) · PubMed · Cited by 367
131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging
Bombardieri, E., Giammarile, F., Aktolun, C., Baum, R. P., Bischof Delaloye, A., Maffioli, L., Moncayo, R., Mortelmans, L., Pepe, G., Reske, S. N., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1545-7 · Cited by 305
Kaltsas, G. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.2.895 · Cited by 275
Koopmans, K. P., Neels, O. C., Kema, I. P., Elsinga, P. H., Sluiter, W. J., Vanghillewe, K., Brouwers, A. H., Jager, P. L., & de Vries, E. G. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1126 · Cited by 238
Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study
Koopmans, K. P., de Vries, E. G., Kema, I. P., Elsinga, P. H., Neels, O. C., Sluiter, W. J., van der Horst-Schrivers, A. N., & Jager, P. L. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70801-4 · Cited by 237
Buck, A. K., Schirrmeister, H., Hetzel, M., Heide, M. V. D., Halter, G., Glatting, G., Mattfeldt, T., Liewald, F., Reske, S. N., & Neumaier, B. (2002) · PubMed · Cited by 213
SPECT/CT hybrid imaging with 111In‐pentetreotide in assessment of neuroendocrine tumours
Krausz, Y., Keidar, Z., Kogan, I., Even‐Sapir, E., Bar‐Shalom, R., Engel, A., Rubinstein, R., Sachs, J., Bocher, M., Agranovicz, S., et al. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01885.x · Cited by 192
Peptide-receptor radionuclide therapy for endocrine tumors
van Essen, M., Krenning, E. P., Kam, B. L. R., de Jong, M., Valkema, R., & Kwekkeboom, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.105 · Cited by 173
Fiebrich, H., Brouwers, A. H., Kerstens, M. N., Pijl, M. E. J., Kema, I. P., de Jong, J. R., Jager, P. L., Elsinga, P. H., Dierckx, R., van der Wal, J. E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1054 · Cited by 162
Molecular imaging in neuroendocrine tumors: Molecular uptake mechanisms and clinical results
Koopmans, K. P., Neels, O. N., Kema, I. P., Elsinga, P. H., Links, T. P., de Vries, E. G. E., & Jager, P. L. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.02.009 · Cited by 151
Belhocine, T., Foidart, J. B., Rigo, P., Najjar, F., Thiry, A., Quatresooz, P., & Hustinx, R. (2002) · Nuclear Medicine Communications · doi:10.1097/00006231-200208000-00005 · Cited by 130
Öberg, K. (2004) · Acta Oncologica · doi:10.1080/02841860410018502 · Cited by 120
Members of Nordic Ne Tumour Group:, Öberg, K., Astrup, L. B., Eriksson, B. K., Falkmer, S. E., Falkmer, S., Gustafsen, J., Haglund, C., Knigge, U., Vatn, M. H., et al. (2004) · Acta Oncologica · doi:10.1080/02841860410018575 · Cited by 105
Self-citationEzziddin, S., Logvinski, T., Yong-Hing, C. J., Ahmadzadehfar, H., Fischer, H., PALMEDO, H., Bucerius, J. A., Reinhardt, M. J., & Biersack, H. (2006) · PubMed · Cited by 86
Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors.
Perri, M., Erba, P., Volterrani, D., et al. (2008) · PubMed · Cited by 85
Srirajaskanthan, R., Watkins, J., Marelli, L., Khan, K., & Caplin, M. E. (2009) · Neuroendocrinology · doi:10.1159/000179899 · Cited by 85
Raderer, M., Kurtaran, A., Leimer, M., Angelberger, P., Niederle, B., Vierhapper, H., Vorbeck, F., Hejna, M., Scheithauer, W., Pidlich, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1331 · Cited by 70
de Geus‐Oei, L., Ruers, T. J. M., Punt, C. J. A., Leer, J. W., Corstens, F. H. M., & Oyen, W. J. G. (2006) · Cancer Imaging · doi:10.1102/1470-7330.2006.9014 · Cited by 52
Binderup, T., Knigge, U., Mogensen, A. M., Hansen, C. P., & Kjær, A. (2008) · Neuroendocrinology · doi:10.1159/000113128 · Cited by 43
Self-citationTakei, T., Kuge, Y., Zhao, S., Sato, M., Strausś, H. W., Blankenberg, F. G., Tait, J. F., & Tamaki, N. (2005) · PubMed · Cited by 38
Zuetenhorst, H. J. M., Taal, B. G., Boot, H., Olmos, R. A. V., & Hoefnagel, C. A. (1999) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199910000-00014 · Cited by 26
Cited by
Recommendations for management of patients with neuroendocrine liver metastases
Frilling, A., Modlin, I. M., Kidd, M., Russell, C., Breitenstein, S., Salem, R., Kwekkeboom, D., Lau, W.-Y., Klersy, C., Vilgrain, V., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70362-0 · Cited by 527
Sundin, A., Arnold, R., Baudin, E., Cwikla, J. B., Eriksson, B., Fanti, S., Fazio, N., Giammarile, F., Hicks, R. J., Kjaer, A., et al. (2017) · Neuroendocrinology · doi:10.1159/000471879 · Cited by 501
Self-citationHowe, J. R., Cardona, K., Fraker, D. L., Kebebew, E., Untch, B. R., Wang, Y.-Z., Law, C. H., Liu, E. H., Kim, M. K., Menda, Y., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000846 · Cited by 376
Gastroenteropancreatic high‐grade neuroendocrine carcinoma
Sorbye, H., Strosberg, J., Baudin, E., Klimstra, D. S., & Yao, J. C. (2014) · Cancer · doi:10.1002/cncr.28721 · Cited by 347
68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors
Poeppel, T. D., Binse, I., Petersenn, S., Lahner, H., Schott, M., Antoch, G., Brandau, W., Bockisch, A., & Boy, C. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.091165 · Cited by 346
Metadata
- Authors
- Binderup, T., Knigge, U., Loft, A., Mortensen, J., Pfeifer, A., Federspiel, B., Hansen, C. P., Højgaard, L., & Kjaer, A.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2010-04-15
- Volume
- 51
- Issue
- 5
- Pages
- 704-712
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W1985381213
- Cited by
- 279
- References
- 33
- FWCI
- 11.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.